- AuthorisedPhase II and Phase III (Integrated)
An International Prospective Study in Children Older than 3 to 5 Years with Clinically Standard-Risk Medulloblastoma with Low-Risk Biological Profile (PNET 5 MB – LR and PNET 5 MB – WNT-HR), average-risk biological profile (PNET 5 MB -SR), or TP53 mutation, and registry for MB ocurring in the context of genetic predisposition
This study is for children aged 3-18 with a type of brain tumour called medulloblastoma. It looks at different ways to treat the tumour, including various chemotherapy drugs, to find the most effective and safest options for different types of medulloblastoma, aiming to improve chances of recovery and quality of life.
For: MedulloblastomaSpain · Netherlands · Czechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
Open-label, Phase 2 study of tusamitamab ravtansine (SAR408701) combined with pembrolizumab and tusamitamab ravtansine (SAR408701) combined with pembrolizumab and platinum-based chemotherapy with or without pemetrexed in patients with CEACAM5-positive expression advanced/metastatic nonsquamous non-small-cell lung cancer (NSQ NSCLC)
This study is testing new combinations of medicines for a type of advanced lung cancer. It combines an experimental drug (tusamitamab ravtansine) with existing treatments like pembrolizumab (Keytruda) and chemotherapy to see how safe and effective they are. It's for adults whose cancer has a specific marker called CEACAM5.
For: CancerFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin with Durvalumab (MEDI4736) and Tremelimumab in intrahepatic cholangiocarcinoma (NeoTreme)
This study is testing a new combination of medicines before surgery for a rare type of liver cancer called intrahepatic cholangiocarcinoma. It aims to see if these medicines can help more patients have successful surgery by making the tumour smaller or easier to remove.
For: intrahepatic cholangiocarcinomaGermany - Active not recruitingPHASE2
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
This study is testing a new cancer medicine called tisotumab vedotin for different solid tumours, including bowel, lung, pancreas, and head and neck cancers. It's looking to see how well it works alone or with other treatments, and what side effects might happen. The study has now moved into a longer-term phase.
For: Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Exocrine Pancreatic CancerUnited States · Canada · France - AuthorisedTherapeutic confirmatory (Phase III)
Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR
This study looks at treating a children's cancer called neuroblastoma. We want to find the best way to treat children who have a lower chance of a severe form of the disease. This will help doctors choose the right treatment to give children the best chance of getting better.
For: low and intermediate risk neuroblastomaGermany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial)
This study looks at extra medicine (chemotherapy) after surgery for certain bile duct or gallbladder cancers. It compares a standard treatment to a new combination, hoping to stop the cancer from coming back and help people live longer and better.
For: Patients after curative intent resection of cholangiocarcinoma (intrahepatic · hilar or distal) or muscle invasive gallbladder carcinoma (without evidence of metastatic disease).Austria · Germany · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently with Platinum-based Chemoradiation Therapy in Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III) (PACIFIC2)
This study looks at a new drug called Imfinzi for people with a type of lung cancer that has spread nearby but can't be removed by surgery. It aims to see if Imfinzi, along with standard treatments like chemotherapy and radiation, helps people live longer and keeps the cancer from growing.
For: Patients with Locally Advanced · Unresectable Non-small Cell Lung Cancer (Stage III)Poland · Hungary - Active not recruitingPHASE3
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
This study looks at a new drug, zanidatamab, combined with chemotherapy, and sometimes another drug called tislelizumab. It aims to see if this treatment works better and is safer than standard chemotherapy for advanced stomach and gullet cancers that have HER2.
For: Gastric Neoplasms · Gastroesophageal Adenocarcinoma · Esophageal AdenocarcinomaArgentina · Australia · Belgium - RecruitingPHASE3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study looks at new treatments for a type of lung cancer where standard treatment has stopped working. It compares a drug called Dato-DXd, alone or with osimertinib, against usual chemotherapy to see which helps patients live longer without their cancer getting worse.
For: Metastatic Non-small Cell Lung CancerUnited States · Australia · Belgium - Active not recruitingPHASE1, PHASE2
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
This study is testing a new cancer medicine, GEN1042, both by itself and with other treatments. It's for people with certain advanced solid tumours where standard treatments haven't worked or aren't available. The main goals are to check its safety and see how well it fights cancer.
For: Malignant Solid Tumor · Non-Small Cell Lung Cancer (NSCLC) · Colorectal Cancer (CRC)United States · Denmark · France - RecruitingPHASE1
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
This study is testing a new drug, Ris-Rez, for people with advanced cancers. Researchers want to see if it's safe, how it works, and if it can help stop cancer growth, both alone and with other medicines.
For: NeoplasmsUnited States · Argentina · Canada - Active not recruitingPHASE3
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
This study compares a new treatment, Atezolizumab, to standard care for patients with early-stage lung cancer after surgery and chemotherapy. It aims to see if Atezolizumab can prevent the cancer from returning and help people live longer.
For: Non-Small Cell Lung CancerUnited States · Australia · Belgium - Active not recruitingPHASE3
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
This study looks at new drug combinations for advanced bladder cancer that hasn't been treated before. It compares them to standard chemotherapy to see if they're safer and work better.
For: Urothelial CancerUnited States · Australia · Austria - Active not recruitingPHASE3
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
This study looks at new drug combinations for advanced lung cancer. It compares a new drug (Datopotamab Deruxtecan) with an existing treatment (Pembrolizumab) and chemotherapy, to see if the new combinations are safer and work better.
For: Metastatic Non Small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
This study compares a new drug, alectinib, with standard chemotherapy for people with a certain type of lung cancer (ALK-positive non-small cell lung cancer) after surgery. We want to see if alectinib is better at stopping the cancer from coming back and if it's safe.
For: Carcinoma, Non-Small-Cell LungUnited States · Australia · Austria - RecruitingPHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
This study is looking at new ways to treat advanced non-small cell lung cancer (a type of lung cancer) that has spread. It compares an experimental drug, rilvegostomig, with a standard drug, pembrolizumab, both given with chemotherapy, to see which works better and is safer.
For: Non-squamous Non-small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
This study looks at a new drug, selpercatinib, for people with a type of lung cancer that has spread. It compares this new drug to standard treatments to see if it's safe and works well for their specific cancer type.
For: Non-Small Cell Lung CancerArgentina · Australia · Belgium - RecruitingPHASE2
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
This study looks at new ways to treat bladder cancer that has spread or can't be removed with surgery. It's testing a drug called sacituzumab govitecan, sometimes on its own, and sometimes with other new treatments, to see if they are safe and effective.
For: Metastatic Urothelial CancerUnited States · France · Germany - Active not recruitingPHASE3
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
This study is looking into a new drug, zipalertinib, for people with a certain type of lung cancer (NSCLC) in its early stages. It compares zipalertinib with standard chemotherapy to a dummy pill (placebo) with standard chemotherapy after surgery.
For: NSCLC, Stage IB-IIIA · Lung Cancer · AdjuvantUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
This study compares new ways to treat advanced lung cancer. It looks at two drug combinations, Nivolumab and Relatlimab plus chemotherapy, versus Pembrolizumab plus chemotherapy. The goal is to find the best treatment for a specific type of lung cancer.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
This study tested new drug combinations for advanced oesophageal cancer. It looked at pembrolizumab with lenvatinib and chemotherapy, versus pembrolizumab and chemotherapy, to see which worked best and was safest. The study has now stopped, with no safety concerns being the reason.
For: Metastatic Esophageal Squamous Cell CarcinomaUnited States · Argentina · Canada - Active not recruitingPHASE1, PHASE2
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
This study investigates new ways to treat advanced bladder cancer (urothelial cancer) that has spread or is locally advanced. It combines a drug called erdafitinib, which targets specific cancer changes, with cetrelimab and/or chemotherapy. The aim is to find safe doses and see how well these treatments work.
For: Urothelial CarcinomaUnited States · Belarus · Belgium - Active not recruitingPHASE3
Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer
This study looks into adding a short course of chemotherapy (Paclitaxel and Carboplatin) before standard chemoradiation for women with locally advanced cervical cancer. The aim is to see if this extra step improves how long women live and if the cancer stays away.
For: Cervical CancerBrazil · India · Italy - RecruitingPHASE3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
This study looks at new drug combinations for stomach (gastric) or food pipe (GEJ) cancer that has a specific marker called HER2. It compares different treatment mixes to see which works best and is safest for advanced cancer.
For: HER2-positive Gastric Cancer · Gastroesophageal Junction AdenocarcinomaUnited States · Argentina · Australia - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
This study is testing new treatments for a type of lung cancer called non-small cell lung cancer. Researchers want to see if a combination of two medicines, calderasib and pembrolizumab, works better than pembrolizumab with chemotherapy to slow down cancer growth.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
This study is testing new combinations of medicines (Zimberelimab and Domvanalimab with chemotherapy) against a standard treatment (Pembrolizumab with chemotherapy) for people with advanced non-small cell lung cancer that hasn't been treated yet. We want to see which combination helps people live longer.
For: Non-small Cell Lung CancerUnited States · Argentina · Austria - Active not recruitingPHASE2
Study of Novel Treatment Combinations in Patients With Lung Cancer
This study looks at new drug combinations to treat lung cancer. It has three parts: for cancer that has spread, cancer that has grown despite previous treatment, and earlier-stage cancer that can be removed by surgery.
For: Lung Cancer · Advanced or Metastatic Non-Small-Cell Lung Cancer · Resectable Non-Small-Cell Lung CancerUnited States · Brazil · Hong Kong - RecruitingPHASE1
A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01
This study is looking into a new treatment called KRC-01 for cervical cancer. It aims to see if KRC-01 is safe, if patients can tolerate it, and if it helps shrink tumours when used with standard treatments like radiotherapy and chemotherapy.
For: Cervical CancerIndia · Thailand · United Kingdom - Active not recruiting
Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy
This study looks at how young children with a type of brain tumour called ependymoma respond to standard chemotherapy. It also checks for long-term side effects to help doctors improve treatment for them in the future.
For: Brain and Central Nervous System Tumors · Cognitive/Functional Effects · Long-term Effects Secondary to Cancer Therapy in ChildrenUnited Kingdom - Active not recruitingPHASE3
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
The CompARE trial is testing new treatments for a type of throat cancer called oropharyngeal cancer. It compares different ways of using radiotherapy, surgery, and immunotherapy to see if they improve survival and quality of life for adults with more advanced forms of this cancer.
For: Oropharyngeal CancerIreland · United Kingdom - RecruitingPHASE3
International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
This study looks at the best way to treat penile cancer that has spread to nearby lymph nodes. It compares surgery alone with surgery after chemotherapy or chemoradiotherapy. It also checks if extra surgery in the pelvis helps prevent cancer from coming back.
For: Squamous Cell Carcinoma of the Penis, Usual TypeUnited States · United Kingdom - Active not recruitingPHASE3
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
This study looks at new ways to treat a type of lung cancer before surgery. We're testing a drug called osimertinib, either alone or with chemotherapy, against chemotherapy by itself. The goal is to see if these new treatments can help more people with resectable non-small cell lung cancer.
For: Non-Small Cell Lung CancerUnited States · Austria · Brazil - Active not recruitingPHASE3
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
This study looks at new ways to treat advanced lung cancer that can't be removed by surgery. It combines standard chemotherapy and radiation with newer drugs, pembrolizumab and olaparib, to see if they can improve survival compared to current treatments.
For: Lung Neoplasms · Carcinoma, Non-Small-Cell LungUnited States · Argentina · Canada - Active not recruitingPHASE3
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
This study is testing a new combination of treatments for adults with advanced lung cancer (NSCLC) that hasn't spread to the brain or spine and doesn't have certain genetic changes. It compares this new treatment to a standard one, hoping it works better.
For: NSCLCUnited States · Austria · Brazil - RecruitingPHASE2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
This study is looking at new ways to treat advanced liver and bile duct cancers. It tests new medicines, called immunomodulators, either on their own or alongside other cancer drugs, to see how well they work and if they are safe.
For: Hepatocellular Carcinoma · Biliary Tract CancerUnited States · China · Hong Kong - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
This study is testing a new combination treatment for bladder cancer that hasn't spread. It combines standard chemotherapy and radiotherapy with a new drug called pembrolizumab, which helps your immune system fight cancer. We want to see if this new combination works better.
For: Urinary Bladder NeoplasmsUnited States · Australia · Chile - Active not recruitingPHASE3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
This study looks at a new combination of medicines, savolitinib and osimertinib, for people with a type of lung cancer that has gotten worse after treatment with osimertinib. It compares this new combination to standard chemotherapy to see if it works better and is safe.
For: Carcinoma · Non-Small-Cell LungUnited States · Argentina · Australia - Active not recruitingPHASE3
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
This study looked at new ways to treat a type of lung cancer called extensive-stage small cell lung cancer (ES-SCLC). It compared a combination of medicines with standard chemotherapy to see if it could help people live longer. The study was changed partway through, so the focus shifted.
For: Small Cell Lung CarcinomaUnited States · Argentina · Australia - RecruitingPHASE2, PHASE3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
This study looks at a new drug, Navlimetostat, combined with standard treatments for advanced lung cancer. It compares this combination to standard treatments alone in patients whose cancer has a specific genetic change called an MTAP deletion. The aim is to see if the new combination works better.
For: Metastatic Non-small Cell Lung Cancer With MTAP DeletionUnited States · Argentina · Australia - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
This study aims to see if adding the drug pembrolizumab to standard chemotherapy before and after surgery helps people with early-stage non-small cell lung cancer live longer and prevent the cancer from returning. It's a large study comparing this new approach with chemotherapy alone.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer
This study looks into a new chemotherapy combination (gemcitabine and cisplatin) compared to the usual care (capecitabine or observation) for people with certain bile duct or gallbladder cancers after surgery. We want to see if the new combination works better.
For: Cholangiocarcinoma · Gall Bladder CarcinomaAustralia · Austria · Denmark - Active not recruitingPHASE3
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
This study is looking at a new treatment for early-stage lung cancer that can be removed with surgery. It combines standard chemotherapy with a newer drug called nivolumab. Researchers want to see if this combination helps people live longer without their cancer returning.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia - RecruitingPHASE3
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
This study looks at new drug combinations for a specific type of advanced lung cancer. It compares a new drug, Divarasib, with Pembrolizumab, against standard treatments to see which works best and is safest for patients with KRAS G12C-mutated non-small cell lung cancer.
For: Non-Small Cell Lung Cancer · KRAS G12C Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
This study is looking at a new treatment called pembrolizumab for advanced or recurrent womb cancer that has a specific genetic marker. It compares this new treatment to standard chemotherapy to see which works better and is safer for women who haven't had chemotherapy for this stage of cancer before.
For: Endometrial NeoplasmsUnited States · Australia · Belgium - Active not recruitingPHASE3
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
This study looks at a new way to treat muscle-invasive bladder cancer using a drug called Durvalumab alongside standard chemotherapy. It aims to see if this combination, given before and after surgery, can improve treatment outcomes and safety for patients.
For: Muscle Invasive Bladder CancerUnited States · Australia · Belgium - RecruitingPHASE3
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
This study looks at new ways to treat high-risk neuroblastoma, a type of cancer, in children and young people. Researchers are testing different combinations of chemotherapy and radiation to find the most effective treatments to help patients live longer and healthier lives.
For: High-Risk Neuroblastoma · Patient With Insufficient Response ChemoimmunotherapyAustralia · Austria · Belgium - RecruitingPHASE2
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
This study is looking into a new medicine called Volrustomig for various advanced cancers, including cervical, head and neck, oesophageal, and mesothelioma. It aims to see how well it works and if it's safe, both on its own and with standard chemotherapy.
For: Sub-study 1 Cervical Cancer (Volrustomig Monotherapy) · Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy) · Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)United States · Australia · Brazil - Active not recruitingPHASE3
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
This study compares two chemotherapy treatments for germ cell tumours that have returned or didn't respond to previous treatment. It looks at a standard chemotherapy plan versus a stronger plan with a stem cell transplant to see which works better.
For: Germ Cell Tumor · Teratoma · ChoriocarcinomaUnited States · Australia · Belgium - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
This study looks at a new drug, pembrolizumab, for certain types of oesophageal cancer. It compares giving pembrolizumab alongside standard chemotherapy and radiotherapy with giving a dummy drug (placebo) with the same standard treatment. We want to see if the new drug can help people live longer or prevent the cancer from coming back.
For: Esophageal Squamous Cell Carcinoma (ESCC) · Gastroesophageal Junction Carcinoma (GEJC) · Esophageal Adenocarcinoma (EAC)United States · Argentina · Belgium - Active not recruitingPHASE3
Paediatric Hepatic International Tumour Trial
This study, called PHITT, is for children and young people up to 30 years old with liver cancers called hepatoblastoma (HB) and hepatocellular carcinoma (HCC). It aims to find better ways to treat these cancers by using tailored treatments and studying them closely.
For: Hepatoblastoma · Carcinoma, HepatocellularAustria · Belgium · Czechia